Effects of Cox-II Inhibitor on Biochemical Markers in Cardiovascular-related Adverse Effects
Information source: National Chung Hsing University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Arthritis
Phase: N/A
Status: Active, not recruiting
Sponsored by: National Chung Hsing University
Summary
The selective cyclooxygenase-2 (COX-2) inhibitors have been associated with increased
cardiovascular risk. The goal of the present study is to investigate the impacts of COX-2
inhibitors on biochemical indices in cardiovascular disease. As the reviewer suggested, the
investigators propose to study the effects of Cox-II inhibitor using experimentally induced
hyperlipidemic rats. Plasma total cholesterol, LDL and triglyceride concentrations will be
determined before and after animals treated with cyclooxygenase-2 (COX-2) inhibitors.
Biochemical markers related to cardiovascular events including prostaglandin I2,
thromboxaneA2 and others will also be investigated. The investigators will also investigate
these biochemical markers in patients taking Celecoxib and NSAIDs. The investigators hope
these studies will reveal clinically useful biochemical markers for cardiovascular events in
patients taking Cox-II inhibitor.
Clinical Details
Study design: Observational Model: Case Control, Time Perspective: Cross-Sectional
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Male/female age >18
- Clinical diagnosed of arthritis
Exclusion Criteria:
- Must not be pregnant/breastfeeding
- Other conditions may lead to exclusion from the trial (e. g. Diabetes mellitus,
malignant melanoma, cardiac conduction disorders, hepatic/renal insufficiency.
Locations and Contacts
Additional Information
Starting date: March 2008
Last updated: July 22, 2009
|